Strategies to Advance Donor Selection Process for Cell Therapies to Improve Outcomes
Recording date: June 17, 2021
HLA matching in the development of cellular therapies and leading-edge allogeneic therapeutics isn’t only about finding the best matches. But also avoiding mismatches that could result in less optimal patient outcomes.
During this on-demand webinar you’ll hear from industry experts about research identifying HLA-B mismatches that are most optimal and which cause negative effects. You will also learn about an automated HLA-B leader matching assessment tool that can be used to help avoid mismatching for HLA-B alleles associated with higher risks for future patients.
Understanding donor HLA characteristics and their impact on the final therapy can ultimately improve allogeneic cell therapy outcomes.
Get insights into:
- The science of the HLA-B leader peptide and its functional role in cell therapy outcomes
- How the HLA-B-leader tool—initially created to support National Marrow Donor Program® (NMDP)/Be The Match® initiatives and research on optimizing HSCT success using mismatched donors—can be used by the cell therapy field in donor source selection
- The impact these tools and research will have on improving patient outcomes in HSCT and emerging cell and gene therapies
- Effie Wang Petersdorf, MD, Professor, Clinical Research Division & Madeline Dabney Adams Endowed Chair in AML Research Fred Hutchinson Cancer Research Center
- Ray Sajulga, Jr., Bioinformatics Scientist NMDP/Be The Match
- Martin Maiers, MS, Vice President of Innovation NMDP/Be The Match
- Kim Wadsworth, Senior Immunogenetic Specialist NMDP/Be The Match